Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease

Cardiovascular Diseases Clinical Trial

Official title:

Double Blinded Study of the Effects of Pioglitazone in Combination With Atorvastatin in Comparison to Atorvastatin Treatment Alone on Intima-Media Thickness in Patients at Risk for Vascular Complications

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00770575
• Other study ID #: ATS K015
• Secondary ID: 2004-004463-30D-
• Status: Completed
• Phase: Phase 2
• First received: October 9, 2008
• Last updated: July 1, 2010
• Start date: June 2005
• Est. completion date: October 2006

Study information

• Verified date: July 2010
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Health authority: European Union: European Medicines Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the effect of pioglitazone, once daily (QD), and atorvastatin combination therapy compared to atorvastatin monotherapy in patients at risk for cardiovascular disease.

Description:

Carotid intima-media thickness is a well described surrogate marker for cardiovascular risk. A thickened carotid intima media layer correlates not only with the presence of cardiovascular risk factors but also the risk of future macrovascular events such as myocardial infarction and stroke. The interventional approach of cardiovascular risk factors with angiotensin converting enzyme system blockers, calcium antagonists or beta blockers can result in reduction of progression or even net regression of carotid intima-media thickness. The most potent agents, however, are statins which have consistently shown effects on carotid intima-media thickness in patients with hypercholesterolemia and/or atherosclerotic disease.

Peroxisome proliferator activator receptor-gamma activation by thiazolidinediones is a promising new approach which reduces insulin resistance and improves lipid profile. In addition to their metabolic activities, peroxisome proliferator activator receptor-gamma activators were shown to exert anti-inflammatory effects, to improve endothelial function and to inhibit atherogenesis in diabetic and in non-diabetic atherosclerosis-prone animal models. Treatment with peroxisome proliferator activator receptor-gamma agonists have shown to reduce arterial pressure and carotid intima-media thickness in diabetic and non-diabetic patients at risk for cardiovascular disease.

The aim of this study is to evaluate the effect of Pioglitazone in addition to Atorvastatin compared to Atorvastatin alone on vascular risk markers and intima-media thickness in patients with elevated risk for cardiovascular disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 148
• Est. completion date: October 2006
• Est. primary completion date: October 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 30 Years to 70 Years

Eligibility

Inclusion Criteria:

• Intima-media thickness of Common Carotid Artery greater than or equal to 0.8 mm (at least on one side).

• Increased cardiovascular risk defined as one or more of the following:

• medical history of infarction

• coronary angiography with proven cardiovascular disease

• instable Angina pectoris

• duplex-sonography of cervical or leg vessels with proven atherosclerotic vascular alterations

• electrocardiogram with ischemia

• stroke

• transient ischemic attack

• peripheral arterial occlusion

• vessel surgery

• hypertension (RR greater than 140/90)

• antihypertensives

• high density lipoprotein less than 40 mg/dl.

• Body mass index greater than or equal to 25 kg/m2.

• Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.

Exclusion Criteria:

• History of overt type-2-diabetes according to the World Health Organization criteria.

• History of type-1-diabetes.

• History of more than one unexplained hypoglycemic episode within the last 6 months.

• Statin therapy within the last 4 weeks.

• Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures.

• History of severe or multiple allergies.

• Treatment with any other investigational drug within 3 months before trial entry.

• Progressive fatal disease.

• Myopathy.

• Drug or alcohol abuse within the last 5 years.

• Smoker defined as patient with evidence or history of tobacco or nicotine use within the last 6 months before the screening visit.

• A history of heart failure (New York Heart Association stage II - IV) or significant respiratory, gastrointestinal, hepatic (glutamate-pyruvate-transaminase time greater than 2.5 times the normal reference range), renal (creatinine greater than 2.0 mg/dl) or hematological disease.

• Blood donation within the last 30 days.

• Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

• ciclosporin

• erythromycin

• clarithromycin

• itraconazole

• ketoconazole

• nefazodone

• niacin

• gemfibrozil and other fibrates

• HIV-Protease-Inhibitors

• Pre-treatment with thiazolidinediones within 3 months before trial entry.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cardiovascular Diseases

Intervention

Drug:
• Pioglitazone and atorvastatin
Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to: Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.
• Atorvastatin
Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the intima-media thickness of the common carotid artery.		Week 24.	No
Secondary	Change in the intima-media thickness of the internal carotid artery.		Week 24.	No
Secondary	Change in the intima-media thickness of the carotid bulbus.		Week 24.	No
Secondary	Change from Baseline in Efficacy Laboratory findings (Interleukin-6, high sensitive C reactive peptide and monocyte chemotactic protein-1)		Week: 24.	No
Secondary	Change from Baseline in Efficacy Laboratory findings (matrix metalloproteinase-9, soluble CD40 Ligand, P-Selectin, soluble intracellular adhesion molecule 1 and soluble vascular cell adhesion molecule 1).		Week: 24.	No
Secondary	Change from Baseline in Efficacy Laboratory findings (adiponectin, tissue plasminogen activator, Plasma glucose, Insulin and Intact proinsulin).		Week: 24.	No
Secondary	Change from Baseline in Efficacy Laboratory findings (blood lipids (total cholesterol, high density lipoprotein, triglycerides) and low density lipoprotein-subfractions).		Week: 24.	No
Secondary	Change from Baseline in Glycosylated Hemoglobin.		Week: 24.	No
Secondary	Change from Baseline in Beta cell function (Homeostatic Model Assessment - beta cell response Score).		Week: 24.	No
Secondary	Change from Baseline in Insulin sensitivity using the Homeostatic Model Assessment - Sensitivity Score).		Week: 24.	No
Secondary	Change from Baseline in Microcirculation assessment.		Week: 24.	No
Secondary	Change from Baseline in Pulse wave velocity.		Weeks: 12 and 24.	No

External Links

•   ACTOS® Package Insert
•   FDA Safety Alerts and Recalls